Cytokinetics, Incorporated 9,803,922 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • May 28th, 2024 • Cytokinetics Inc • Pharmaceutical preparations
Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,803,922 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,470,588 additional shares (the “Optional Securities”) of common stock, par value $0.001 (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
